How and When to Decide on Revascularization in Stable Ischemic Heart Disease.

Slides:



Advertisements
Similar presentations
Rate of Obstructive Coronary Disease in Elective Diagnostic Cath Manesh R. Patel, MD Assistant Professor of Medicine Director Cath Lab Research – Duke.
Advertisements

“ If physicians would read two articles per day out of the six million medical articles published annually, in one year, they would fall 82 centuries behind.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery 2007 ACC/AHA and 2009 ESC GUIDELINES.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Arthur Stillman, M.D., Ph.D., PI Pamela Woodard, M.D., Study Co-chair Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic.
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
Myocardial Ischemia Redefined: Optimal Care in CAD.
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
Redefining Treatment Strategies for Optimal Medical Care in CAD COURAGE and MERLIN-TIMI 36.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
Contemporary Management of Myocardial Ischemia
? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for.
Women reaching equality in health, despite the differences Nowadays women remain the largest CAD population subgroup being under-diagnosed and under-treated.
Survival Benefits in Higher Risk Patients Coronary Revascularization has Revolutionized the Therapy of Ischemic Heart Disease Acute coronary syndromes.
Choosing Wisely: Cardiology Jeffrey Ziffra D.O. Mercy Medical Center – North Iowa 10/14/2016.
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology The Elusive Role of Myocardial Perfusion Imaging in.
William E. Boden, MD, FACC, FAHA
Clinical need for determination of vulnerable plaques
Diabetic Dyslipidemia in Practice
Trends in Coronary Procedures per 1000 Medicare Beneficiaries
SAVOR-TIMI 53 Summary SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke.
New Guidelines to Prevent SCD: What You Need to Know
Atrial Fibrillation and PCI
SIHD Guidelines. Personalized Medicine: Applying Guidelines to the Individual Patient With SIHD.
Optimizing Therapy for Osteoarthritis
Risk Stratification in PAH: What Do the Latest Data Suggest?
A Paradigm Shift in PAH.
NOACs, AF, and PCI: What Do the Latest Data Suggest?
Addressing Patients at High Risk for SCA
Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)
Unmet Needs in the Secondary Prevention in ACS
Select Topics in Cardiovascular Medicine
New Perspectives in AF and PCI: Implications for the Practicing Physician.
Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.
Recurrent Angina: New Tools for an Old Problem
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
Terms of Use. Terms of Use.
Need to Know! Screening and Diagnosis of Kidney Disease in Diabetes
Considerations for Percutaneous Coronary Intervention (PCI)
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.
A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.
Evaluating LDL-C Recommendations
CV Risk Doesn't End in the Cath Lab
AF and PCI in Practice.
Understanding PAD.
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Remote Patient Management:
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Type 2 Diabetes Management:  Where Are We Heading in Our Efforts to Control CV Risk?
Atrial Fibrillation.
CV Risk Doesn't End in the Cath Lab
Updates in Cardiovascular Medicine
Identifying High-Risk AF Patients
The European Society of Cardiology Presented by RJ De Winter
Duration of Dual Antiplatelet Therapy
CAD/PAD in Primary Care
CAD and HF Often Coexist
FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.
Pharmacotherapy for Diabetic Coronary Disease:
Typical Patient Presentation
The Challenge of AF and PCI: Practical Strategies to Improve Outcomes
Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?
Factor Xa Inhibitors in Coronary Artery Disease
Lipids, the Heart, and the Kidney
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
Presentation transcript:

How and When to Decide on Revascularization in Stable Ischemic Heart Disease

REACH Registry Increased Risk for CV Death or MI in Patients With Stable Angina vs Risk Factors or No Angina

Microvascular Disease With Angina Increases Risk

Goals of Angina Management in Established CVD

IMPROVE-IT Ezetimibe + simvastatin vs simvastatin

Noninvasive Risk Stratification

Noninvasive Risk Stratification (cont)

Risk Stratification and Therapeutic Implications

Appropriateness of Invasive Testing for Diagnosis of SIHD

Revascularization to Improve SIHD Symptoms

COURAGE Revascularization vs Optimal Medical Therapy

Guidelines on Anti-Ischemic Medications for Symptom Relief in SIHD

Factors Affecting Antianginal Therapy

Revascularization to Improve Survival in Patients with SIHD

MERLIN TIMI 36 Ranolazine vs Placebo Reduces Ischemic Symptoms in Patients Undergoing PCI

Recurrent Angina After PCI

RIVER-PCI

Summary

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)